7-Ethyl-10-Hydroxycamptothecin

Spécifications

86639-52-3Numéro CAS

643-093-9Numéro CE

(19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dioneNom IUPAC

C22H20N2O5Formule chimique

392.4 g/molMasse molaire

7-Ethyl-10-hydroxycamptothecin; 86639-52-3; SN-38; SN 38 lactone; SN 38; 10-Hydroxy-7-ethylcamptothecin; NK-012; 7-Ethyl-10-hydroxy-20(S)-camptothecin; NK 012; NK012; 0H43101T0J; CAMPTOTHECIN, 7-ETHYL-10-HYDROXY-; CHEBI:8988; DTXSID4040399; (4S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (4S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione; (1S,2S,3R)-1-(3,4-dihydroxy-5-methoxy-phenyl)-2,3,7-trihydroxy-3-(hydroxymethyl)-6-methoxy-tetralin-2-carboxylic acid; 1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE, 4,11-DIETHYL-4,9-DIHYDROXY-, (4S)-; H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4,11-diethyl-4,9-dihydroxy-, (S)-; (19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo(11.8.0.02,11.04,9.015,20)henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4,11-diethyl-4,9-dihydroxy-, (4S)-; RefChem:914300; 7 Ethyl 10 hydroxycamptothecin; DTXCID2020399; 7-Ethyl-10-hydroxy-camptothecin; (S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; MFCD00871873; SN38; C22H20N2O5; 7-10-hydroxycamptothecin; (19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione; IT-141; NSC673596; 113015-38-6; LE-SN38; Captothecin, 7-ethyl-10-hydroxy-; UNII-0H43101T0J; 7-Ethyl-10-hydroxycamptothecin ((S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione); AvaChem1025; SN-38 (Standard); (+)-7-ETHYL-10-HYDROXYCAMPTOTHECIN; diethyl(dihydroxy)[?]dione; SCHEMBL34018; GTPL6925; orb1307686; orb3141304; SN 38 [WHO-DD]; SCHEMBL29354078; SCHEMBL29359781; 10-hydroxy-7-ethyl camptothecin; 10-hydroxy-7-ethyl-camptothecin; EX-A989; HMS3413B12; HMS3652P12; HMS3677B12; HMS3753E15; 7-Ethyl-10-hydroxy-20(S)-CPT; BDBM50418088; EBC-11025; HY-13704R; MSK162382; s4908; AKOS015920433; AC-1357; CCG-264764; CS-1579; DB05482; FE29579; NSC-673596; SN-38(NK-012)?; NCGC00167831-01; NCGC00167831-05; NCGC00167831-09; (S)-4,11-diethyl-4,9-dihydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione; 110714-48-2; AS-13533; BP-24513; Camptothecin 7-Ethyl-10-Hydroxy Impurity; HY-13704; NCI60_026056; SY013197; E0748; NS00069821; SW219948-1; S-(+)-7-ETHYL-10-HYDROXYCAMPOTHECIN; EN300-122379; F046379; Q1750127; BRD-K89561498-001-01-7; BRD-K89561498-001-02-5; 7-Ethyl-10-hydroxycamptothecin, >=98% (HPLC), powder; Z1541759909; Irinotecan EP Impurity E; Camptothecin 7-Ethyl-10-Hydroxy Impurity; (19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione; (4S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)dione, AldrichCPR; (S)-4,11-Diethyl-4,9-di-OH-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; 1H-Pyrano[3',7]indolizino[1,2-b]quinoline- 3,14(4H,12H)-dione, 4,11-diethyl-4,9-dihydroxy-, (4S)-; RS4Synonymes